29k is a non-profit organization and community dedicated to making personal growth accessible and free for everyone. Through their Aware platform, they provide evidence-based psychological tools that are scalable and user-friendly, aiming to foster mental health, inner development, and civic leadership. With over 400,000 users and a high average rating, 29k is positioned as a leader in the mental health space, focusing on creating healthy environments and promoting sustainable societal growth. Their unique approach combines empirical research with technology to facilitate meaningful personal change.

Access to Finance Rwanda (AFR) is a Rwandan not-for-profit organization, established in March 2010 by the governments of the United Kingdom (UK) and Rwanda to promote financial inclusion and financial sector development. Existing funders of AFR include the UK Foreign and Commonwealth Development Office (FCDO), the Mastercard Foundation, Sweden, and Jersey Overseas Aid (JOA). AFR’s strategic focus is stimulating financial sector development by partnering with financial institutions and other stakeholders to increase access to and use of quality financial services. We identify and address constraints that prevent the financial market from reaching Rwanda’s low-income population and support Rwanda’s economic growth and promote innovations and learning that result in sustainable change in the financial sector. Improving access to financial services for the rural poor, women, youth, refugees, persons with disabilities, and SMEs is a particular focus. AFR is guided by the market system.

AQS is a Rwandan-based startup passionate about unleashing data's power. We specialize in providing customized solutions that enable decision-makers across industries to turn complex data into actionable insights. Our co-creation process is at the core of everything we do. We believe in working collaboratively with our clients to understand their unique needs and goals, providing tailored solutions that meet their requirements. Our team of experts includes data scientists, analysts, and business strategists who have extensive experience in analyzing and interpreting complex data. We use state-of-the-art technology and advanced analytics tools to transform messy and unstructured data into powerful insights that drive better decision-making and improve business outcomes. At AQS, we are committed to empowering decision-makers in Rwanda and beyond to harness the power of their data. Data-driven insights can drive innovation, improve efficiency, and enable growth across industries.

The Africa's Business Heroes competition is the Jack Ma Foundation’s flagship philanthropic entrepreneur program in Africa. We aim to identify, spotlight, and support African entrepreneur heroes creating impact in their communities and building a more inclusive economy for the future. You can learn more about our finalists on https://africabusinessheroes.org/en/ Monday to Saturday, 9:00 AM - 5:00 PM CAT (GMT+2) Phone/WhatsApp: +250 792575614

The African Youth and Adolescents Network on Population and Development Rwanda Chapter (AFRIYAN Rwanda), founded in 2016, is one of the largest youth-led networks in Rwanda. It represents, connects, and engages every day with youth-led organizations that aim to advance Sexual and Reproductive Health and Rights (SRHR), gender promotion, youth empowerment, and leadership through the Meaningful and Inclusive Youth Participation (MIYP) in policy and decision making at different levels.

Agteria Biotech is focused on reducing global greenhouse gas emissions, particularly methane from cattle, through its innovative AB-01 feed additive. This patent-pending solution effectively reduces methane emissions at a cost significantly lower than current alternatives. The company aims to scale its production to meet global demand, making it a viable option for farmers worldwide. With a strong scientific backing and partnerships with leading research institutions, Agteria is positioned to make a substantial impact in the agricultural sector while promoting sustainability.

The idea for AI-BOB originated from Elin's frustration after many years as a real estate developer and expert in building regulations. Construction errors and delays were more the norm than the exception, resulting in unnecessarily costly building projects. Determined to find a solution, she and her team developed a smart, AI-driven solution that revolutionizes the approach to architectural design, compliance checks, and official reports. At AI-BOB, we are committed to making building regulations accessible, comprehensible, and seamlessly integrated into your workflow. This facilitates more efficient and accurate construction planning, ultimately enabling a more sustainable future.

Aidoc is a pioneering force in clinical AI. We focus on aiding and empowering healthcare teams to optimize patient outcomes, which results in improved economic value and clinical outcomes. Our clinically proven AI solutions eliminate silos, increase efficiencies, and improve outcomes by delivering critical information when and where care teams need it, leading to immediate collective action. Built on Aidoc’s exclusive AIOS™, we analyze and aggregate medical data to enable care teams to operationalize the unexpected and work seamlessly with a continued focus on the patient. Aidoc AI is always on, running in the background to change the foreground. For safety information on Aidoc’s products, please visit our safety and compliance page on our website.

Airforestry's groundbreaking technology makes it possible to thin out the forests in a completely new way, namely from the air with high-capacity drones. Through our innovative thinning, we contribute to reducing carbon dioxide emissions from forestry work while increasing the forest's ability to sequester carbon.

Akagera Medicines is developing novel liposomal formulations of antibacterial drugs to treat Tuberculosis. The company was founded in 2018 in Kigali, Rwanda. It is well-funded, majority-owned by the people of Rwanda, incorporated as a Delaware corporation, and has laboratories in Boston and San Francisco. Board members and advisors include Ambassador Dr. Albrecht Conze, Dr. Paul Farmer, Dr. Donald Kaberuka, and Dr. Anne Lenaerts. Akagera Medicines intends (if toxicology and proof of concept efficacy studies go as anticipated) to begin IND-enabling studies in Q4 2020. The moral purpose of Akagera Medicines is to create medicines that lead to a world free of Tuberculosis (TB), humankind’s greatest killer. This means improving efficacy, shortening the duration of treatment, optimizing drug/drug interaction, eliminating toxicity, and lowering the costs to patients and to society. Our goals • To initiate clinical trials in humans in 2022; • To reduce the global incidence of TB deaths.